Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis

A Multicenter, Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01563185

Enrollment

Registered

2012-03-26

Start date

2012-04-30

Completion date

2015-03-31

Last updated

2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Juvenile Idiopathic Arthritis

Keywords

JIA, ibuprofen, famotidine, pediatrics, for > 1 month

Brief summary

The primary objective of this Phase 4, multi-center, open-label study is to evaluate the safety and tolerability of DUEXIS in Juvenile Idiopathic Arthritis (JIA) patients aged 10 years to 16 years, 11 months, treated up to 24 weeks. The secondary objectives are to evaluate the PK characteristics of DUEXIS in JIA patients and to evaluate the signs and symptoms of JIA in patients aged 10 years to 16 years, 11 months receiving DUEXIS for up to 24 weeks.

Detailed description

Approximately 30 JIA patients who meet all eligibility criteria and who are expected to require daily administration of an NSAID for up to 24 weeks will be enrolled. A subset of approximately 6 patients will participate in a single dose PK study at Day 0 with an abbreviated PK profile performed at Week 4 if possible. Multiple dose PK sampling will occur in all enrolled patients. Study with completed results acquired from Horizon in 2024

Interventions

DRUG800 mg ibuprofen/26.6 mg famotidine

Oral tablet taken three time per day

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

10 Years to 16 Years

Healthy volunteers

Inclusion criteria

1. Patient and guardian are willing to consent to undergo up to 24 weeks of treatment with DUEXIS (ibuprofen 800 mg/famotidine 26.6 mg) oral tablet three times daily. 2. Patient is male or female, aged 10 years to 16 years, 11 months. 3. Patient is diagnosed with JIA for \> 1 month including oligoarthritis, polyarthritis rheumatoid factor (RF) +, polyarthritis RF-, psoriatic arthritis, enthesitis-related arthritis, or undifferentiated and systemic arthritis without systemic features in the past 6 months. 4. Patient must have currently active articular disease as defined by \> 1 active joint (i.e., presence of swelling, or if no swelling is present, limitation of motion \[LOM\] accompanied by pain, tenderness, or both). 5. Based upon investigator judgment, given current treatment patient is receiving and level of disease activity, it is determined appropriate for the patient to undergo up to 24 weeks of treatment with DUEXIS (ibuprofen 800 mg/famotidine 26.6 mg) oral tablet three times daily. The investigator will use his/her clinical judgment in determining the duration of treatment for the patient based on the standard of care up to 24 weeks of treatment. 6. Weight \> 48 kg and body mass index (BMI) \> 5th percentile using the Centers for Disease Control (CDC) BMI percentile calculator for child and teen at the screening visit. 7. Patient is able to swallow a DUEXIS tablet whole. 8. For the single dose pharmacokinetic (PK) subset, patients and guardians must be willing to participate in the serial blood sample collections at Day 0 and Week 4. 9. Female patients of childbearing potential and male patients must agree to use medically acceptable methods of contraception, including abstinence, throughout the entire study period. 10. Patient is willing and able to comply with the prescribed treatment protocol and evaluations.

Exclusion criteria

1. Patient has a history of or experienced any of the following: * NSAID-associated and/or primary peptic ulcer disease-associated serious gastrointestinal complications such as perforation of ulcers, gastric outlet obstruction due to ulcers, and/or acute gastrointestinal bleeding * NSAID-induced asthma exacerbation, acute renal failure, interstitial nephritis, and/or hepatitis * Malignant disease of the gastrointestinal tract * Erosive esophagitis * Coronary artery bypass graft (CABG) surgery within the 14 days prior to study Day 0 * Uncontrolled diabetes mellitus as evidenced by Hemoglobin A1c \> 7% * Known history of human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C. 2. Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, neurological, or cerebral disease. 3. JIA disease is severe as defined by either physician's or parent's global assessments \> 90 on a 100 point scale. 4. Systemic JIA with any of the following manifestations within the last 6 months prior to enrollment: intermittent fever due to JIA, rheumatoid rash, hepatosplenomegaly, pleuritis, pericarditis, or macrophage activation syndrome. 5. Active uveitis. 6. Presence of any other rheumatic disease or major chronic infectious, inflammatory, immunologic disease (e.g., inflammatory bowel disease, hypogammaglobulinemia, or systemic lupus erythematosus, etc.). 7. Presence at screening or history of any disease other than JIA that requires the use of chronic systemic corticosteroids. 8. History of clinically significant drug or alcohol abuse. 9. Presence at screening of any of the following laboratory values: * Hemoglobin \< 9.0 g/dL * White blood cells \< 2000/mm\^3 (2 x 109/L) * Platelets \< 150,000/mm\^3 (150 x 109/L) * Serum creatinine \> 1.5 times upper limit of normal * Serum ALT or AST \> 2.0 times upper limit of normal * H. pylori positive * Any other lab value that in the opinion of the investigator might place the patient at unacceptable risk for participation in this study. 10. Methotrexate \> 20 mg/M\^2/week or \> 40 mg/week. 11. Patient currently is participating in an investigational drug study, or patient participated in an investigational drug study within the 30 days (or \< 5 terminal half-lives of elimination) prior to study entry. 12. Females who are pregnant or breast feeding. 13. Female patient has a positive serum pregnancy test at Screening and/or a positive urine pregnancy test at Study Day 0. 14. Patient has a concomitant disease or condition that, in the opinion of the Investigator, could interfere with the conduct of the study or could put the patient at unacceptable risk

Design outcomes

Primary

Measure	Time frame	Description
Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)	Day 0 through Week 26/ET (adverse event data was collected at every visit, including telephone visits)	Safety assessments included AE monitoring, concomitant medication review, physical examinations (including vital signs and weight), and clinical laboratory assessments, including pregnancy testing for female patients. The outcome measure data table below describes the TEAEs experienced by patients.

Secondary

Measure	Time frame	Description
American College of Rheumatology (ACR) Pediatric Core Measures: Physician's Global Assessment of Disease Activity and Parent's Assessment of Overall Well-being	Baseline to Endpoint (Endpoint is the last post-baseline value obtained, as two subjects did not complete the study up until week 24).	The following 2 ACR pediatric Core Measures of JIA activity and the parent's assessment of discomfort were quantitatively assessed at baseline and each study visit: the physician's global assessment of disease activity and the parent's global assessment of overall well-being. These ACR values represent the average change in the physician's global assessment of disease activity and the parent's global assessment of overall well-being from the baseline visit to the week 24/ET visit. The ACR pediatric core measure: Physician's global assessment of disease activity and parent's assessment of overall well being was measured on a scale of 0-100 mm (0 = very good, 100=very poor).
American College of Rheumatology (ACR) Pediatric Core Measures: CHAQ - Disability Index	Baseline to Endpoint (Endpoint is the last post-baseline value obtained, as two subjects did not complete the study up until week 24).	The following ACR pediatric Core Measure of JIA activity and the parent's assessment of discomfort were quantitatively assessed at baseline and each study visit: CHAQ - Disability Index. This ACR measurement represents the average change in the Childhood Health Assessment Questionnaire (CHAQ) - Disability Index from the baseline visit to the week 24/ET visit. The CHAQ disability index is measured on a scale of 0-3 (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do).
ACR Pediatric Components by Time Point: Number of Joints With Active Arthritis and the Number of Joints With Limited Range of Motion Number of Joints With Active Arthritis	Baseline to Endpoint (Endpoint is the last post-baseline value obtained, as two subjects did not complete the study up until week 24).	The following 2 ACR pediatric Core Measures of JIA activity and the parent's assessment of discomfort were quantitatively assessed at baseline and each study visit: number of joints with active arthritis and the number of joints with limited range of motion. These ACR values represent the average change in number of joints with active arthritis and the number of joints with limited range of motion from the baseline visit to the week 24/ET visit. The joints that were assessed include the right and left temporomandibular, sternoclavicular, arcomiclavicular, shoulder, elbow, wrist, MCP - 1. MCP - 2, MCP - 3, MCP - 4, MCP - 5, PIP - 1, PIP - 2, PIP - 3, PIP - 4, PIP - 5, DIP - 1, DIP - 2, DIP - 3, DIP - 4, and DIP - 5.
American College of Rheumatology (ACR) Pediatric Core Measures: Serum C Reactive Protein (CRP) Concentration	Baseline to Endpoint (Endpoint is the last post-baseline value obtained, as two subjects did not complete the study up until week 24).	The following ACR pediatric Core Measure of JIA activity and the parent's assessment of discomfort were quantitatively assessed at baseline and each study visit: CRP Concentration. This ACR value represents the average change in Serum C Reactive Protein (CRP) Concentration from the baseline visit to the week 24/ET visit. The normal range referenced was 0 mg/L - 4.99 mg/L.
Childhood Health Questionnaire Parent Form 50 (CHQ-PF50) Scores	Baseline to Endpoint (Endpoint is the last post-baseline value obtained, as two subjects did not complete the study up until week 24).	To assess patient quality of life while on study medication, the CHQ was administered to the patients' parent or guardian on Day 0 and at the Week 24/ET visit. The raw scale scores were transformed into scores on a 0 to 100 scale, 100 indicating best health and 0 indicating worst health. The algorithm is: Transformed Score = ((Actual Raw Score - Lowest Possible Raw Score)/(Possible Raw Score Range)) x100. The actual raw score is the mean of the item responses in a scale (sum of item responses/number of completed items). The possible raw score range is the highest possible raw score minus the lowest possible raw score. The outcome measure data table shows the average change in the CHQ concepts from Baseline to the week 24 visit. The average change in the CHQ concepts is on a -100 to 100 scale, -100 representing a negative change in health and 100 indicating a positive change in health.
Single Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Maximum Observed Concentration (Cmax)	Pre-dose, and 0.5, 1, 2, 4, 8 hours post-dose	Cmax was estimated for ibuprofen and famotidine. The PK parameters for ibuprofen and famotidine represent average Cmax values following a single oral dose of DUEXIS. Samples were collected pre-dose and at 0.5, 1, 2, 4, and 8 to 10 hours following study drug administration.
Single Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Area Under the Concentration-time Curve From the Time of Dosing to the Last Measurable Concentration (AUC(0-t))	Pre-dose, and 0.5, 1, 2, 4, 8 hours post-dose	AUC(0-t) was estimated for ibuprofen and famotidine. The PK parameters for ibuprofen and famotidine represent average AUC values following a single oral dose of DUEXIS. Samples were collected pre-dose and at 0.5, 1, 2, 4, and 8 to 10 hours following study drug administration.
Multiple Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Individual Oral Clearance (CL/F)	Pre-dose and 0.5, 1, 2, 4, and 8 hours post-dose in the single dose group; sparse samples at random times in the multiple dose group	CL/F was estimated in ibuprofen and famotidine.
Multiple Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Volume Distribution (V/F)	Pre-dose and 0.5, 1, 2, 4, and 8 hours post-dose in the single dose group; sparse samples at random times in the multiple dose group	V/F were estimated in ibuprofen and famotidine.
Single Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Time of Maximum Observed Concentration (Tmax)	Pre-dose, 0.5, 1, 2, 4, 8 hours post-dose	Tmax was estimated for ibuprofen and famotidine.The PK parameters for ibuprofen and famotidine represent average Tmax values following a single oral dose of DUEXIS. Samples were collected pre-dose and at 0.5, 1, 2, 4, and 8 to 10 hours following study drug administration.

Countries

United States

Participant flow

Participants by arm

Arm	Count
DUEXIS 800 mg ibuprofen/26.6 mg famotidine 800 mg ibuprofen/26.6 mg famotidine: Oral tablet taken three time per day	12
Total	12

Withdrawals & dropouts

Period	Reason	FG000
Overall Study	Non-Compliance with study drug	1
Overall Study	Withdrawal by Subject	1

Baseline characteristics

Characteristic	DUEXIS
Age, Categorical <=18 years	12 Participants
Age, Categorical >=65 years	0 Participants
Age, Categorical Between 18 and 65 years	0 Participants
Age, Continuous	13.8 years STANDARD_DEVIATION 1.71
Region of Enrollment United States	12 participants
Sex: Female, Male Female	5 Participants
Sex: Female, Male Male	7 Participants

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	— / —
other Total, other adverse events	12 / 12
serious Total, serious adverse events	0 / 12

Outcome results

Primary

Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)

Safety assessments included AE monitoring, concomitant medication review, physical examinations (including vital signs and weight), and clinical laboratory assessments, including pregnancy testing for female patients. The outcome measure data table below describes the TEAEs experienced by patients.

Time frame: Day 0 through Week 26/ET (adverse event data was collected at every visit, including telephone visits)

Arm	Measure	Group	Value (NUMBER)
DUEXIS	Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)	TEAE: General disorders	2 participants
DUEXIS	Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)	TEAE: Skin and subcutaneous tissue disorders	2 participants
DUEXIS	Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)	Any patient with at least 1 TEAE	12 participants
DUEXIS	Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)	Any patient with at least 1 mild TEAE	7 participants
DUEXIS	Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)	At least 1 moderate TEAE	5 participants
DUEXIS	Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)	At least 1 severe TEAE	0 participants
DUEXIS	Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)	A possibly related TEAE	2 participants
DUEXIS	Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)	SAE	0 participants
DUEXIS	Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)	A TEAE leading to study drug discontinuation	0 participants
DUEXIS	Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)	A TEAE leading to death	0 participants
DUEXIS	Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)	TEAE: Gastrointestinal Disorders	4 participants
DUEXIS	Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)	TEAE: Infections and infestations	7 participants
DUEXIS	Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)	TEAE: Injury, poisoning & procedural complications	2 participants
DUEXIS	Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)	TEAE: Muscoskeletal & connective tissue disorders	2 participants
DUEXIS	Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)	TEAE: Nervous system disorders	1 participants
DUEXIS	Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)	TEAE:Respiratory, thoracic & mediastinal disorders	3 participants

Secondary

ACR Pediatric Components by Time Point: Number of Joints With Active Arthritis and the Number of Joints With Limited Range of Motion Number of Joints With Active Arthritis

The following 2 ACR pediatric Core Measures of JIA activity and the parent's assessment of discomfort were quantitatively assessed at baseline and each study visit: number of joints with active arthritis and the number of joints with limited range of motion. These ACR values represent the average change in number of joints with active arthritis and the number of joints with limited range of motion from the baseline visit to the week 24/ET visit. The joints that were assessed include the right and left temporomandibular, sternoclavicular, arcomiclavicular, shoulder, elbow, wrist, MCP - 1. MCP - 2, MCP - 3, MCP - 4, MCP - 5, PIP - 1, PIP - 2, PIP - 3, PIP - 4, PIP - 5, DIP - 1, DIP - 2, DIP - 3, DIP - 4, and DIP - 5.